Pieris Pharmaceuticals (NASDAQ:PIRS) had its target price hoisted by HC Wainwright from $9.00 to $12.00 in a research report report published on Tuesday morning, MarketBeat reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock.

Other equities analysts have also issued reports about the stock. BidaskClub upgraded shares of Pieris Pharmaceuticals from a hold rating to a buy rating in a report on Wednesday, December 27th. ValuEngine lowered shares of Pieris Pharmaceuticals from a hold rating to a sell rating in a report on Friday, December 1st. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. Pieris Pharmaceuticals presently has a consensus rating of Buy and a consensus target price of $10.00.

Pieris Pharmaceuticals (NASDAQ PIRS) traded up $0.43 during mid-day trading on Tuesday, hitting $7.35. 638,571 shares of the stock traded hands, compared to its average volume of 497,655. Pieris Pharmaceuticals has a 1 year low of $1.66 and a 1 year high of $7.90. The stock has a market capitalization of $329.24, a price-to-earnings ratio of -10.07 and a beta of -76.25.

Pieris Pharmaceuticals (NASDAQ:PIRS) last released its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.05. Pieris Pharmaceuticals had a negative net margin of 321.83% and a negative return on equity of 221.93%. The firm had revenue of $3.93 million during the quarter, compared to analyst estimates of $1.52 million. The firm’s revenue was up 400.3% compared to the same quarter last year. equities research analysts anticipate that Pieris Pharmaceuticals will post -0.72 earnings per share for the current year.

In related news, major shareholder Orbimed Advisors Llc sold 1,709,620 shares of the business’s stock in a transaction that occurred on Wednesday, January 3rd. The shares were sold at an average price of $7.35, for a total value of $12,565,707.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 4.05% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Creative Planning raised its holdings in Pieris Pharmaceuticals by 18.2% in the 4th quarter. Creative Planning now owns 78,025 shares of the biotechnology company’s stock worth $589,000 after acquiring an additional 12,000 shares during the last quarter. Bank of Montreal Can purchased a new position in Pieris Pharmaceuticals in the 4th quarter worth approximately $144,000. Wells Fargo & Company MN purchased a new position in Pieris Pharmaceuticals in the 3rd quarter worth approximately $105,000. JPMorgan Chase & Co. purchased a new position in Pieris Pharmaceuticals in the 3rd quarter worth approximately $600,000. Finally, New York State Common Retirement Fund raised its holdings in Pieris Pharmaceuticals by 107.5% in the 3rd quarter. New York State Common Retirement Fund now owns 33,000 shares of the biotechnology company’s stock worth $190,000 after acquiring an additional 17,100 shares during the last quarter. Institutional investors own 50.45% of the company’s stock.

TRADEMARK VIOLATION WARNING: “HC Wainwright Increases Pieris Pharmaceuticals (PIRS) Price Target to $12.00” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2018/01/17/hc-wainwright-increases-pieris-pharmaceuticals-pirs-price-target-to-12-00.html.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.